Document Detail

Impact of Pharmacologic Interventions-Treating Endothelial Dysfunction and Group 2 Pulmonary Hypertension.
MedLine Citation:
PMID:  25446553     Owner:  NLM     Status:  Publisher    
Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging prelimiray data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.
Marco Guazzi; Mardi Gomberg-Maitland; Robert Naeije
Related Documents :
22475523 - Polymorphisms of angiotensin ii type 1 receptor gene and those of angiotensinogen point...
22387483 - Prevalence and predictors of slow flow in angiographically normal coronary arteries.
145933 - Silent unilateral pulmonary venous obstruction. occurrence after surgical correction of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-11
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  -     ISSN:  1873-1740     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is ...
Next Document:  Benefits of exercise training on coronary blood flow in coronary artery disease patients.